Breast cancer radiation cut to just 9 days in new trial
NCT ID NCT03345420
First seen Oct 31, 2025 · Last updated Jun 22, 2026 · Updated 41 times
Summary
This phase II trial tested a 9-day course of whole breast radiation (hypofractionated radiotherapy) in 102 patients with early-stage breast cancer (stages 0-IIB). The goal was to see if a shorter treatment schedule could maintain good cosmetic outcomes and quality of life while reducing side effects. Participants received higher daily doses over fewer days compared to standard radiation.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for INVASIVE BREAST CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Huntsman Cancer Institute/University of Utah
Salt Lake City, Utah, 84112, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
hypofractionated radiation therapy
What this could lead to
If successful, this could offer a shorter, more convenient radiation schedule for early breast cancer patients with fewer side effects and good cosmetic results.
What could go wrong
This is a phase II trial with only 102 participants, so results are preliminary. The shorter schedule may not be as effective or well-tolerated in larger, more diverse populations.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.